A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

NCT00034957

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

COMPLETED PHASE2

Effectiveness of KOS-862 in the Treatment of Lung Cancer

NCT00080509

Lung Cancer

TERMINATED PHASE2

Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3

NCT00273507

Non-small Cell Lung Cancer

TERMINATED PHASE3

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

NCT03377023

Non Small Cell Lung Cancer Lung Cancer, Nonsmall Cell Non Small Cell Lung Cancer Metastatic

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

NCT02321540

Lung Cancer

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

MK-0457

Group Type OTHER

MK0457

Intervention Type DRUG

IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0457

IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are at least 18 years of age with cancer of the lung and who have had either no previous treatment or 1 previous treatment for advanced cancer of the lung. Certain other treatments may also be allowed (prior cytotoxic chemotherapy in the adjuvant setting)

Exclusion Criteria

* Patients who have had treatment with any investigational therapy within the past 30 days are not eligible.
* Patients who have had a disease or medical condition that is not controlled will not be eligible.
* Patients who are pregnant or breastfeeding are not eligible.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No